Later on, it was shown that general NF-κB inhibitors led to massive inflammation in mice by increasing IL1-β secretion and inflammasome activation [81], thus questioning the suitability of these inhibitors for cancer therapy. The gene discussed is NFKB1; the disease is cancer.